Kornimate/medical-research-clean huggingface dataset:
function and pain following knee replacement

Conditions: Knee Arthropathy; Post Operative Pain; Pain, Postoperative

Summary: the goal of this interventional study is to compare pain management techniques (femoral nerve block, intra-articular block, none) in tka patients. the main questions it aims to answer are: * are there differences in postoperative outcomes? * does preoperative quadriceps muscle strength predict early functional ability? participants underwent tka and assessments. researchers compared pain management techniques to assess effects on postoperative outcomes and identified the importance of preoperative quadriceps muscle strength as a predictor of early functional ability. further research is required to refine postoperative pain management strategies.

total knee arthroplasty (tka) is a frequently undertaken elective orthopedic intervention for severe knee osteoarthritis, frequently yielding postoperative discomfort and complications. peripheral nerve blocks, notably femoral nerve blocks, are commonly utilized for analgesia but may transiently impede motor nerve function, weakening the quadriceps muscle. intra-articular blocks offer a potential alternative to mitigate motor impairment. however, there exists a dearth of information regarding the comparative effectiveness of these methods with respect to short-term functional outcomes in the immediate postoperative phase following tka. objectives: this study assesses functional outcomes, pain, quadriceps strength after tka with femoral nerve block, intra-articular block, and a control group. it identifies predictors of postoperative functional ability. methods: 54 patients undergoing tka were evaluated, measuring pre-op quadriceps strength, and utilizing the oxford knee score for functionality. post-op, we evaluated mobility using the timed up \& go, elderly mobility scale, and five times sit-to-stand tests on pod 1 \& 3/4. pain levels, hospitalization, surgical duration, complications, and falls were also recorded.

Eligibility criteria:
inclusion criteria: * men and women, over the age of 18, electively assigned for primary knee replacement surgery. * asa score 1-3 exclusion criteria: * revision surgery * patients suffering from chronic pain syndrome or chronic opioid use. * patients with previous neurological deficits in the lower extremities. * a cognitive state that does not allow signing of consent or understanding simple instructions.

Keywords: post operative pain total knee replacement total knee arthroplasty pain post operative function nerve block intra-articular block
nc xperience pmcf study( repic04b)

Conditions: Coronary Artery Disease (CAD); Ischemic Heart Disease

Summary: multicenter, prospective, non-randomized, post-market clinical follow-up (pmcf) study to confirm and support the clinical safety and performance of nc xperience to meet eu medical device regulation (mdr) requirements in all the consecutive patients treated with nc xperience .

the objective of this multicenter, prospective, non-randomized, post-market clinical follow-up (pmcf) study is to confirm and support the clinical safety and performance of the nc xperience in a non-selected, real world population under daily clinical practice when used as intended by the manufacturer to meet eu medical device regulation requirements for post-market clinical follow-up.

Eligibility criteria:
inclusion criteria: * patient treated with nc xperience according to routine hospital practice and following instructions for use * informed consent signed exclusion criteria: * not meet inclusion criteria

Keywords: mdr (medical device regulations) pmcf (post-market clinical follow-up) coronary balloon dilatation catheter
effects of hypertonic dextrose water injection for supraspinatus tendinosis patients

Conditions: Chronic Shoulder Pain

Summary: using hypertonic dextrose water for chronic supraspinatus tendinosis and using ultrasound as assessment tool to evaluate the effect of intervention.

supraspinatus tendinosis is a degenerative process of tendon. it can be caused by external trauma episode and imbalanced of self-repair process. it can cause patients with shoulder pain when shoulder over head exercise and heavy lifting. it can also influence the sleep quality due to pain symptoms of shoulder. usually these patients had limited response to medication and physical modality. moreover, it can cause shoulder tear or rupture, which can disability with aging. prolotherapy is an injection therapy for chronic painful musculoskeletal conditions. it involves the injection of small volumes of an irritant agent, most commonly a hyperosmolar dextrose solution, at multiple painful tendon and ligament insertions where they connect to bone, over several treatment sessions. the injection of an irritant solution initiates an inflammatory cascade at the site of injection, which causes fibroblast proliferation and subsequent collagen synthesis, resulting in a stronger tendon or ligament. hyperosmolar dextrose appears to be the most commonly used agent today, with morrhuate sodium used slightly less often. there is promising recent evidence for prolotherapy, with hyperosmolar dextrose in treating painful tendinopathies. the aim of this study is to hypertonic injection in supraspinatus tendinosis patients about clinical and ultrasound image presentation. we conducted a double blinded randomized controlled trial for 60 participants with chronic shoulder pain for 3 months with supraspinatus tendonsis. in study group, one injection with 20% dextrose water was injection in supraspinatus tendon and control group received normal saline and lidocaine. spadi, vas and ultrasound data were obtained before intervention and 2 weeks, 6 weeks and 12 weeks after injection after intervention. the anova and independent t test are applied for analysis by spss 20.0 with p value less than 0.05 as statistical significance.

Eligibility criteria:
inclusion criteria: * aged more than 20 years old with diagnosis of chronic supraspinatus tendinosis by ultrasound and clinical shoulder pain lasting for more than 3 months exclusion criteria: * history of shoulder fracture and operation, with frozen shoulder or full thickness rupture of rotator cuff, steroid, or hyaluronic acid, or platelet rich plasma (prp) injection during the period of intervention and following up

Keywords: dextrose prolotherapy patients
neurocognition after radiotherapy in cns- and skull-base tumors

Conditions: Cognition; Brain Tumor; Magnetic Resonance Imaging; Meningioma; Glioma; Pituitary Adenoma

Summary: the goal of this multicenter prospective longitudinal study is to study the long-term impact of multimodal treatment (chemotherapy, radiotherapy and surgery) in adult brain and base of skull tumors on neurocognitive functioning. all included patients will complete a self-report inventory (subjective cognitive functioning, qol, confounders), a cognitive test battery, an advanced mr at multiple timepoints. moreover, toxicity will be scored according to the ctcaev5.0 in these patients over time.

this study will combine mr imaging techniques together with elaborate neuropsychological assessments and rt dosimetry in 120 patients who will be examined baseline (before rt) and followed longitudinally after rt. the first objective is to build an ntcp model for neurocognitive decline after rt (for each cognitive domain separately), linking dose-volume parameters to structures within the brain susceptible to neurological damage and neurocognitive decline after radiotherapy. these ntcp models can be used to make predictions on neurocognitive decline in future primary brain tumour patients receiving cranial rt. the second objective is to evaluate dose-dependent neurocognitive decline. in particular, the investigators will assess: * prevalence and severity of neurocognitive decline after rt for all cognitive domains * brain structures or functional brain connections important in neurocognitive functioning (based on dedicated mri). * dose-dependencies of specific neurocognitive skills after rt in adult brain tumour patients * correlations between rt dosimetry and early brain changes (mri)

Eligibility criteria:
inclusion criteria: * adult patients (≥ 18 years at the time of diagnosis) with a primary brain or base of skull tumour, who are amenable for conventionally fractionated radiotherapy (photon or proton irradiation) exclusion criteria: * patients with tumours with poor prognostic characteristics: * incompletely resected idh-wild-type glioma * completely resected idh-wild-type and mgmt-promotor unmethylated glioma * grade iii meningioma * h3k27m+ midline glioma * patients with tumours requiring craniospinal irradiation (csi)/whole ventricular irradiation (wvi) * hypofractionated/stereotactic radiation (fraction sizes \> 2 gy per fraction) * inability to perform the cognitive tests or self-report inventories because of motor/sensory deficits or insufficient dutch language proficiency * mental retardation documented before diagnosis * pre-diagnosis/pre-existing psychiatric diagnosis resulting in cognitive deficits like psychoses, neurodevelopmental disorders (autism/learning disorders) * relapse previously treated by chemo and/or radiation therapy * genetic syndrome (e.g. down) * unable to perform mr imaging (claustrophobia, metallic implants like pacemaker/icd/neurostimulator)
efficiency of using argon plasma coagulation in weight regain in patients following gastric bypass

Conditions: Bariatric Surgery Candidate

Summary: among the techniques of bariatric surgery, the gastric y bypass according to roux (rygb) allows greater weight loss and more lasting over time than sleeve gastrectomy and gastric banding. however, around 20% of patients will regain weight within 24 months after surgery. among the many mechanisms that lead to weight regain, we can mention distension of the gastric pouch and gastro-jejunal anastomosis. a reoperation is then necessary. argan plasma coagulation intervention (apc) by endoscopy allows to reduce the caliber of the gastro-jejunal anastomosis. the aim of the study is to show the efficacy of apc associated with multidisciplinary medical management and to compare it with multidisciplinary medical management alone in weight regain of patients.


Eligibility criteria:
inclusion criteria: * be between 18 and 65 years old. * have had a gastric bypass in y more than 2 years ago * have a weight regain of more than 10% of the lowest weight after the first intervention. * have benefited from a multidisciplinary medico-psychological reassessment. * understand the interest of the study and agree to long-term follow-up. * agree to be included in the study and have signed a consent form in a free and informed manner. * be affiliated with health insurance. * for female patients of childbearing potential, have an effective method of contraception exclusion criteria: * presence of a disease unrelated to obesity that is life-threatening. * pregnancy or wish to become pregnant within the year. * "breastfeeding" patients * female patients of childbearing age and unable or unwilling to use an effective method of contraception * presence of an unhealed gastric ulcer or stenosis of the gastrointestinal anastomosis * presence of a psychiatric pathology compromising the proper understanding of the study or patient under guardianship or guardianship. * patient not understanding french or unable to give consent. * patient already included in a study or in conflict of interest with this study.
post marketing observational study on venezuelan patients with psoriasis

Conditions: Moderate to Severe Chronic Plaque Psoriasis

Summary: the aim of this study is to obtain venezuelan data of clinical effectiveness, impact in the hrqol, work productivity and activity impairment in patients with psoriasis using adalimumab.


Eligibility criteria:
inclusion criteria: * subjects with moderate to severe chronic plaque psoriasis, with or without psoriatic arthritis, who have the indication for adalimumab because they need systemic therapy or because they have had failure to phototherapy, or to other systemic or topical treatments * subjects that are not receiving biologic therapy in the last 12 weeks or classical therapy in the past 4 weeks and/or phototherapy in the last 2 weeks. topical therapy will be allowed, to a constant dose and will not be used within 24 hours prior to the visit * patients under previous treatment with any experimental drug will have a minimum washout period of five half-lives * subjects must be capable to understand and willing to give a written informed consent form to release information and to comply with the requirements of the study protocol exclusion criteria: * subjects should not be enrolled if they cannot be treated in accordance with the local product label approved in venezuela * subjects enrolled into another study or under treatment with an investigational product * history of viral hepatitis b infection or hiv * history of neurologic symptoms suggestive of central nervous system demyelinating disease * history of cancer or lymphoproliferative disease (other than successfully treated non-melanoma skin cancer or localized carcinoma in situ of the cervix) * active tb infection before initiating adalimumab treatment or latent tb infection not able to complete prophylactic treatment * pregnant or lactating female. pregnancy will be tested before entering the study in fertile women. women in fertile age must be advised by the physician, to use a clinically accepted contraceptive method (contraceptive pills, iuds, barrier devices as condoms or abstinence) * history of congestive heart failure (chf) * any another condition that according to the criteria of the participating investigator represents an obstacle for study conduction and / or subjects to an unacceptable risks * subjects with active infection including chronic or localized infections until infections are controlled * history of sensitive to latex or other component of the syringe * subjects who requires concomitant phototherapy and systemic therapy during adalimumab therapy

Keywords: psoriasis related to health quality of life patient reported outcomes venezuelan patients
treatment of challenging macular holes using plasma rich in growth factors

Conditions: Macular Holes

Summary: aim of the study:to report the structural and visual outcomes of plasma rich in growth factors in closure of challenging macular holes

challenging full thickness macular holes ( ftmh) include : recurrent ftmh persistent (refractory) ftmh macular holes in eyes with pathological myopia large macular holes with an inner diameter of more than 650 µm. plasma rich in growth factors (prgf) is characterized by a moderate concentration of platelets, in the absence of leukocytes. this absence of leukocytes is based on the fact that they synthesize matrix metalloproteinases, free radicals, and proinflammatory cytokines, which do not contribute and even impair the altered tissue regeneration aim of the study:to report the structural and visual outcomes of plasma rich in growth factors in closure of challenging macular holes

Eligibility criteria:
inclusion criteria: 1. age ≥18 years 2. challenging ftmh which include recurrent macular holes persistent(refractory) macular holes macular holes in eyes with pathological myopia large macular holes with an inner diameter of more than 650 µm exclusion criteria: * 1-corneal opacities 2-glaucomatous patients 3-co-existing macular pathology ( e.g. diabetic retinopathy, vein occlusion and age related macular degeneration ) 4-history of ppv for any reason other than ftmh
study on 'the use of non-contrast helical computerized tomogram in predicting treatment outcomes of upper ureteric stone by extracorporeal shock wave lithotripsy using the sonolith 4000+ lithotripter'

Conditions: Ureteral Calculi

Summary: the purpose of this research is to assess the role of non-contrast helical computerized tomogram in predicting the treatment outcome of upper ureteric stone by extracorporeal shock wave lithotripsy (eswl).


Eligibility criteria:
inclusion criteria: * adult patient (\> 18 years old) * with solitary upper ureteric stone (defined as ureter above the sacroiliac joint as seen on plain radiography) diagnosed by nchct \*(\* can have stones at the other site but the indexed stone is a solitary stone) * size 5 to 15 mm in the maximal diameter as measured from plain radiography. * planned for primary in-situ eswl exclusion criteria: * patient contraindicated for eswl - active urosepsis, coagulopathy, pregnant lady etc * presence of percutaneous nephrostomy or ureteric stent * suspected distal obstruction

Keywords: upper ureteric stone
the relation between uric acid level and endothelial dysfunction in patients with polycystic kidney disease

Conditions: Polycystic Kidney, Autosomal Dominant

Summary: there are substantial data demonstrating increased endothelial dysfunction, inflammation and oxidative stress in patients with autosomal dominant polycystic kidney disease (adpkd), the association between serum uric acid level and endothelial dysfunction has not been elucidated yet in these patients. therefore, in this study, the investigators aimed to examine the relationship between the uric acid level and the ed in normotensive adpkd patients with preserved renal function.

this is the first study to evaluate the relationship between uric acid and endothelial dysfunction in patients with early stage adpkd

Eligibility criteria:
inclusion criteria: * adpkd patients with normal renal function, * normotensive adpkd patients exclusion criteria: * patients with impaired kidney function, * atherosclerotic disorders, * diagnosis of hypertension, gout, diabetes, * using of insulin, thiazide, allopurinol or uricosuric drugs

Keywords: uric acid polycystic kidney disease
vnp40101m in treating patients with richter syndrome or refractory or relapsed chronic lymphocytic leukemia or other lymphoproliferative disorders

Conditions: Leukemia; Lymphoma

Summary: rationale: drugs used in chemotherapy, such as vnp40101m, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. purpose: this phase i/ii trial is studying the side effects and best dose of vnp40101m and to see how well it works in treating patients with richter syndrome or refractory or relapsed chronic lymphocytic leukemia or other lymphoproliferative disorders.

objectives: * determine the maximum tolerated dose (mtd) of vnp40101m in patients with richter syndrome or refractory or relapsed chronic lymphocytic leukemia or other lymphoproliferative disease. (phase i) * determine the toxic effects of this drug in these patients. (phase i) * determine the efficacy, as determined by overall response rate, of this drug at the mtd determined in phase i in these patients. (phase ii) outline: this is a phase i dose-escalation study followed by a phase ii study. * phase i: patients receive vnp40101m iv over 30 minutes on day 1. courses repeat every 3-6 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. cohorts of 3-6 patients receive escalating doses of vnp40101m until the maximum tolerated dose (mtd) is determined. the mtd is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. at least 6 patients are treated at the mtd. * phase ii: patients receive vnp40101m at the mtd determined in phase i. projected accrual: a total of 35 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * diagnosis of 1 of the following hematologic malignancies: * fludarabine refractory or relapsed chronic lymphocytic leukemia (cll) * cll in transformation allowed * richter syndrome * other refractory lymphoproliferative diseases patient characteristics: * ecog performance status 0-2 * creatinine ≤ 2.0 mg/dl * renal dysfunction due to organ infiltration by disease allowed * ast and alt ≤ 3 times upper limit of normal (uln) (unless due to organ infiltration by disease) * bilirubin ≤ 1.5 times uln (unless due to gilbert's syndrome) * not pregnant or nursing * negative pregnancy test * fertile patients must use effective contraception * no uncontrolled infection * no symptomatic coronary artery disease * no arrhythmia not controlled by medication * no uncontrolled, symptomatic congestive heart failure * no myocardial infarction within the past 3 months * no other uncontrolled illness * no psychiatric illness or social situation that would preclude study compliance prior concurrent therapy: * at least 2 weeks since prior cytotoxic therapy except in patients with rapidly progressing disease * no other concurrent standard or investigational treatment for this cancer * no other concurrent cytotoxic investigational drugs * no concurrent disulfiram

Keywords: refractory chronic lymphocytic leukemia recurrent adult diffuse large cell lymphoma recurrent adult hodgkin lymphoma
evaluation of the arm rehabilitation device for patients with stroke

Conditions: Stroke

Summary: the usability assessment focuses on the actual use of the proposed rehabilitation system to clarify issues users would face in actual system operation, thus providing a reference for subsequent system improvement.

this study protocol was approved by the institutional review board of chang gung medical foundation. the usability assessment focuses on the actual use of the proposed rehabilitation system to clarify issues users would face in actual system operation, thus providing a reference for subsequent system improvement. pre-testing and formal testing were conducted at chang gung memorial hospital at taoyuan. the pre-test was conducted on five healthy participants, while the formal testing was conducted on 12 participants (4 stroke patients, 4 caregivers, and 4 therapists). the healthy participants were aged 20-70 years old and had no physical disabilities; the stroke patients had normal cognitive and language skills, stable stroke status, no fractures in the upper limbs in the previous three months, and minimal or no upper limb spasticity with modified ashworth scale of 0 or 1; the occupational therapists should had work experience in the hospital for more than one year. prior to the experiment, the subject provided basic biographical information. the investigators then explained the experimental process and demonstrated the operation of the device. for usability assessment, the subject operated the device under the instruction by the researchers, during which problems observed and questions asked were recorded. following device operation, the subjects filled the system usability scale (sus) questionnaire that obtained subjective evaluations and recommendations for the device. experimental instrument consisted of the rehabilitation device, video cameras, still image cameras, digital voice recorders, questionnaires and observational recording forms. the results of the sus questionnaire were analyzed using spss (ibm corp., armonk, ny, usa). the split-half method was used for reliability analysis and one-sample t test for comparison.

Eligibility criteria:
inclusion criteria: * had previous experience using rehabilitation equipment. exclusion criteria: * cognitive deficits or psychiatric illness.